Session » ACR Late-Breaking Abstract Oral Session
-
Abstract Number: L2
Proteome-Wide Analysis and CXCL4 As a Pathogenic Biomarker in Systemic Sclerosis
-
Abstract Number: L3
A Phase 2b, 12-Week Study of VX-509, an Oral Selective Janus Kinase 3 Inhibitor, in Combination with Background Methotrexate in Rheumatoid Arthritis